Title : Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.

Pub. Date : 2022 Feb

PMID : 34862634






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Twelve new triazolo(4,3-a)quinoxaline-based compounds are reported as anticancer agents with potential effects against vascular endothelial growth factor receptor-2 (VEGFR-2), using sorafenib as a reference molecule. Sorafenib kinase insert domain receptor Homo sapiens
2 The most powerful VEGFR-2 inhibitor was compound 14a, which had an IC50 value of 3.2 nM, which is very close to that of sorafenib (IC50 = 3.12 nM). Sorafenib kinase insert domain receptor Homo sapiens